Pfizer Inc., a leading global biopharmaceutical company headquartered in the United States, has been at the forefront of medical innovation since its founding in 1849. With a strong presence in North America, Europe, and Asia, Pfizer operates across various sectors, including vaccines, oncology, and rare diseases. The company is renowned for its core products, such as the COVID-19 vaccine and groundbreaking cancer therapies, which leverage advanced biotechnology to address unmet medical needs. Pfizer's commitment to research and development has positioned it as a market leader, consistently achieving significant milestones in drug discovery and patient care. With a robust portfolio and a reputation for quality, Pfizer continues to shape the future of healthcare, making a profound impact on global health outcomes.
How does Pfizer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pfizer's score of 97 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Pfizer reported total emissions of approximately 1,080,000,000 kg CO2e for Scope 1 and 2, while Scope 3 emissions from business travel and downstream transportation and distribution amounted to about 188,000,000 kg CO2e and 154,000,000 kg CO2e, respectively. For 2023, Pfizer's emissions included approximately 620,124,000 kg CO2e for Scope 1, 486,384,000 kg CO2e for Scope 2, and a significant 4,338,487,000 kg CO2e for Scope 3. Pfizer has set ambitious climate commitments, aiming for a 46% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2019 baseline. This target aligns with their goal to achieve net-zero emissions across their operations by 2040. Additionally, they plan to reduce Scope 3 emissions related to business travel by 25% and upstream transportation and distribution by 10% by 2025, both from a 2019 baseline. Furthermore, Pfizer is committed to ensuring that 64% of its suppliers by spend covering purchased goods and services will have science-based targets by 2025. These initiatives reflect Pfizer's commitment to sustainability and reducing its carbon footprint, contributing to global efforts to combat climate change.
Access structured emissions data, company-specific emission factors, and source documents
2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - |
Scope 2 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - |
Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pfizer is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.